Introduction
Mitral valve regurgitation is the most common valvular disorder in the United States, affecting 1 in 10 patients over the age of 75. 1, 2 The etiology is most often degenerative primary valve disease, for which the gold standard treatment remains surgical mitral valve repair. 3 While repair has been shown to have superior short-and long-term outcomes to mitral valve replacement in this cohort, reports analyzing national trends in mitral valve repair have found that it is being performed at an insufficient rate. 4, 5 Furthermore, of those patients with degenerative leaflet pathology 75% are referred for surgery late in the course of their disease with associated worse outcomes. 4 It is clear that in patients with severe degenerative mitral regurgitation, mitral repair should be performed prior to the onset of adverse ventricular remodeling and symptomatic heart failure. However, current repair rates vary widely from institution to institution, and even in those centers that perform repair routinely some patients may be felt to be at too high risk to undergo standard repair with cardiopulmonary bypass. 4 New techniques that facilitate mitral valve repair while avoiding some of the morbidity of conventional repair may be of merit.
Transapical echocardiography-guided beating-heart placement of artificial cords has the potential to help patients with degenerative mitral regurgitation in several ways. By decreasing the invasiveness and morbidity of repair, this technique may encourage earlier referral of asymptomatic patients. Similarly, by avoiding a large incision and cardiopulmonary bypass, this approach may be valuable in patients in whom conventional mitral repair is felt to be associated with high operative risk.
Independent of these benefits, there are technical advantages to this approach that allow surgeons to perform a more physiologic repair. Because the chords are implanted and their lengths adjusted in real time on a beating heart under transesophageal echocardiography, the physiologic impact of the polytetrafluoroethylene (PTFE) chords can be observed in real time. By seeing the beat-by-beat effect of the intervention the operator can optimally adjust the position and length of the chords to ensure the prolapse or flail segment has been corrected, the mitral regurgitation is resolved, and adequate coaptation has been achieved to ensure a durable repair. This is in marked contrast to placing PTFE chords on the arrested heart under direct vision during which the only guidance on chordal length is direct inspection and the only way to inspect the quality of repair is injecting saline to inflate the arrested ventricle.
There have been 2 investigational devices to facilitate this procedure: the NeoChord DS1000 and the Harpoon Mitral Valve Repair System (Supplemental Video). Both of these devices are positioned through the left ventricular wall adjacent to the apex to allow the placement of one or more artificial chords near the edge of a prolapsed or flail portion of a mitral leaflet. By applying tension to these chords and affixing them at an appropriate length the abnormality can be corrected and the impact on regurgitation and mitral valve coaptation observed in real time.
The NeoChord DS1000 mechanically grasps the leaflet before piercing it with a specially designed needle carrying the expanded PTFE (ePTFE) chord. After a girth hitch knot is tied and slid to the leaflet the 2 free ends of the chord are fixed to the periapical ventricular wall. In contrast, the Harpoon device is much smaller and uses a preformed PTFE knot wrapped around a 21-gauge needle, which, when the delivery system abuts the leaflet, is driven through and then rapidly withdraws causing the ePTFE to unwrap and knot on the atrial side of the leaflet (Fig. 1) . The Harpoon chords can be implanted only on the P2 segment of the posterior leaflet.
The NeoChord DS1000 was the first published technology with an animal study entering print in 2009. 6 A proof-ofconcept study published in 2014, the TACT trial, 7 showed that Editorial of 30 patients with severe mitral regurgitation (MR) due to isolated prolapse of the posterior leaflet, 17 patients had MR ≤2+ at 30 days. The procedure was refined throughout the course of the trial and those patients operated on later tended to do better. Six of these patients were followed long-term, and at the 5-year mark 5 patients had no-trace MR and showed a trend toward reversal of left ventricular remodeling. 8 The TRACER trial 9 examined the effects of the Harpoon system on a cohort of 30 patients with similar pathology to those discussed earlier. Successful reduction of MR to less than or equal to moderate was achieved in 90% of patients at 30 days. At 6-month follow-up, 22 of these patients had minimal MR, 2 had moderate MR, and 2 had severe MR. The suboptimal outcomes of these 4 patients in particular were attributed to poor intraoperative imaging, selection issues (advanced mitral annular calcification), and in 1 instance leaflet perforation due to operator error. Interestingly, tensioning of the artificial chords created an annuloplasty effect with a 31% reduction in mitral annular area and a 19% reduction in septal-lateral dimension. Long-term data have not yet been generated for the Harpoon device.
The success of either of these devices is predicated on selecting the right patient, placing the correct number of chords in the correct locations, and adjusting them to the correct length. Like any new technology, there is a learning curve. We have attempted to summarize some of the key points in our 10 commandments of transapical off-pump chordal replacement that will ensure success of these new technologies.
Thou Shalt Not Perform Beating-Heart ePTFE Chords on the Incorrect Patient!
Like any technology, picking the right patient is paramount to success. At the present time, this technology works best for correcting isolated, focal, segmental prolapse of the P2 segment of the posterior leaflet for the Harpoon device, and focal A2/P2 segment prolapse or flail for the NeoChord device. Ideally patients should have anterior leaflet length allowing the creation of a generous zone of coaptation when the prolapsing segment is pulled into the ventricle.
Patients that should be excluded include those with severe calcification of the mitral leaflets or annulus, extensive leaflet segment pathology including clefts, functional or ischemic mitral regurgitation, and a dilated annulus. As the technology improves and usage becomes more widespread, it is possible that a large percentage of patients with degenerative mitral valve disease with isolated pathologies can benefit from this approach.
Thou Shalt Maintain Equipoise!
Quality cannot be compromised. We have excellent outcomes on standard surgical valve repair and outcomes of beating-heart chordal replacement must be comparable. Current studies have shown that a majority of patients who undergo beating-heart chords have minimal-to-no residual mitral regurgitation, low postsurgical valvular gradients, and short-and mid-term (for the NeoChord DS1000) outcomes that match conventional repair, provided the anatomy is suitable. The durability is lesser and recurrent mitral regurgitation more frequent with anterior and more complex leaflet pathology. As with all new technology surgeons considering adoption in practice must maintain equipoise. Be critical in self-evaluating as the operation proceeds, listen to your echocardiographer during the procedure, follow patients closely afterwards, and scrutinize outcomes. Above all else we must do no harm; we should not make martyrs for the cause of advancing technology.
Thou Shalt Ensure Durability of Repair!
This technology and technique need to afford a minimal amount of stress to the leaflets. Wherever the chords anchor also needs to be relatively stress free. One strategy for decreasing stress on the chords is to implant more of them-more chords mean less stress distributed to each individual chord and a more even distribution of stress across the leaflet itself. It is generally not recommended to implant fewer than 3 chords in a patient. Chords should be placed across the entire free edge of the prolapsed segment, with 3 to 4 mm spacing between each knot or chordal pair. It is also possible to repair secondary chords with Harpoon device if needed. An important lesson learned in trials of the NeoChord DS1000 is that the chords should be anchored to a point just adjacent to the ventricular apex where the myocardium is thick and the chords anchor well. 
Thou Shalt Maximize the Zone of Coaptation!
An effective postrepair coaptation surface can be accurately predicted with either a ratio of the posterior prolapse segment length to the anterior-posterior mitral diameter minimum of 1.5:1 9 or an anterior mitral leaflet that is >65% the length of the anterior-posterior mitral diameter. Due to the transapical approach of these technologies, concurrent annuloplasty is not performed; therefore, any patients with a significantly dilated annulus should be avoided. There is annuloplasty effect present with use of the Harpoon device that results in a 20% reduction of the anterior-posterior diameter.
It remains unclear if earlier intervention on a valve with a less dilated annulus obviates this mainstay of mitral valve surgery. Current development of transcatheter annuloplasty rings may enable a multimodal approach to fix complex mitral pathology in patients unable or unwilling to undergo more invasive and complex procedures.
Transseptal Is Thine King, Thou Shalt Hold No Approaches Above Transseptal!
In other technologies, avoiding left ventricular apical access has been a successful strategy. Results with standard retrograde arterial transcatheter aortic valve replacement (TAVR) have been superior to results obtained with transapical TAVR. 10, 11 Transseptal approaches have been successfully utilized in the treatment of atrial fibrillation and in the MitraClip device. A transseptal approach allows an operator to avoid puncturing both arteries and the ventricular wall, mitigating the risks of free bleeding and the ingress of air.
Clearly, technical hurdles exist that complicate the utilization of transseptal access in beating-heart chords. Transapical access enjoys the benefit of direct continuity of motion and force facilitating accurate chordal placement and precise dynamic chordal tensioning. Replicating this through indirect control in the setting of distant venous access is a problem for which no one has provided compelling evidence of a solution thus far.
Several newer devices have been designed from the ground up to enable transseptal delivery. The ChordArt system had a first-in-man study published in September 2018 12 and 1-year follow-up data currently in press, which show stable resolution of mitral regurgitation. 13 Pipeline Medical recently revealed promising outcomes of first-in-human application of the Pipeline mitral repair system. 14 The NeoChord company is also working on a second-generation device and is attempting to engineer a solution allowing transseptal access. It is possible that this field will split in the near future between transseptal technologies allowing true minimal invasiveness and transapical technologies allowing ease of precise implantation.
Cherish Thine Echocardiographer!
The most important aspect of beating-heart mitral valve repair is the quality of the images used to plan and to guide the procedure. It is essential to create a targeting plan prior to the operation to predict optimal placement of the chords. Moreover, reevaluation of the anatomy after each chord is placed and adjusted is vital in ensuring optimal coaptation is achieved. A skilled echocardiographer with experience in beating-heart structural valve interventions is crucial to obtain optimal outcomes. Simultaneous orthogonal 2-dimensional images (bicommisural and long-axis) must be used.
Multiple transesophageal echocardiographic platforms should be tested when training in the animal lab and only those that allow adequate visualization of the delivery system should be used in the operating room. Suboptimal image quality due to either the transesophageal echocardiogram platform or echocardiographer error can result in chordal misplacement or leaflet damage.
Whatever your platform and whoever your echocardiographer, ensure that chords can be implanted within 2 mm of the intended target. While most prolapse occurs on the focal P2 segment, and while these have been the patients included in trials beating-heart chords technology, accurate imaging of the anterior leaflet is also critical. Experts anticipate that this technology will be applicable to all forms of degenerative mitral valve prolapse as operative technique improves. Recently, the NeoChord DS1000 has been used to treat focal A2 segmental prolapse on the anterior leaflet. 15 
Thou Shalt Not Covet Another Surgeon's Surgical Exposure!
In the large majority of cases, a very small 4 cm incision is possible, rib-spreading is not necessary and can be avoided with careful planning of the incision and use of a soft-tissue retractor. The surgeon should use surface echocardiography to identify the optimal incision location. The ventricle should be entered approximately 2 cm basal to the true apex, and approximately 1 cm lateral to the left anterior descending coronary artery. The entry site should be perpendicular to the mitral annular plane such that the shaft of the delivery system can cross into the left atrium without interacting with either mitral leaflet. Importantly, this location is far away from any conduction pathways and coronary arteries.
Let There Be Ease of Chordal Length Adjustment!
Appropriate leaflet height is important in maximizing coaptation and minimizing leaflet stress. It is critical that devices allow accurate, dynamic, and intuitive adjustment of chordal length. Currently little overtensioning of the chords is recommended given the acute ventricular remodeling that occurs after mitral regurgitation has been eliminated. Patients who did not have overtensioning of the chords have been found to have subsequent recurrent mitral regurgitation and is the single most important predictor of procedural failure. In fact, it has been reported that intraprocedural systolic anterior motion can be corrected through slight chordal shortening. 9 So long as leaflet restriction and pseudo-prolapse do not occur, coaptation will be maximized and mitral dynamics will be optimized.
Thou Shalt Preserve the Patient's Future Options!
These devices have a key benefit when compared to the current standard for transvenous edge-to-edge mitral valve repair, the MitraClip, in that the only intracardiac implant remaining after the procedure is the PTFE chord. It has been observed that MitraClip placement can lead to fibrosis of proximal tissue and, therefore, preclude future attempts at mitral valve repair. 16 Similar fibrotic changes have not been seen on patients who underwent beating-heart chordal placement. 7-9 Also patients after NeoChord or Harpoon chord implantation are not limited to subsequent mitral repair or replacement techniques. Any intervention can be performed after Harpoon and NeoChord. Surgical repair is rarely possible after MitraClip.
We Must Be Bold and Embrace New Technology for the Forward Progression and Survival of our Field Depends on it!
Whether it be transapical or transseptal, it is vital for surgeons to be proactive in learning and utilizing this new technology. While open surgical mitral valve repair has been shown to durably resolve mitral regurgitation and has an excellent safety profile, patients stand to benefit from a procedure with a less invasive, percutaneous approach. It is our duty as providers to familiarize ourselves with the spectrum of cutting-edge technologies available for use and to investigate what offerings may benefit our practices. The future of mitral valve repair is in less invasive, percutaneous approaches. 17
Conclusions
Given the prevalence of degenerative mitral valve disease and the degree to which patients benefit from repair, the rate of mitral repair remains disappointingly low. There are barriers to care centers beginning repair programs, and in those programs that have been established there are limitations to which patients can be treated. In solving these problems, we do not need hunt for the future…we have already found it. Beating-heart mitral valve chord technology allows earlier, easier, and arguably safer intervention and has the potential to revolutionize and expand access to mitral valve repair, sparing many patients from the downward spiral of adverse cardiac remodeling and progressive heart failure.
